Pancreatic Cancer
Pancreatic NETs differ biologically from pancreatic ductal adenocarcinoma.
Learn MoreUnderstanding Neuroendocrine Tumor Diagnosis
Neuroendocrine tumor diagnosis is a layered process because NETs can begin in different organs, grow at very different rates, and either release hormones or remain clinically silent. GastroDoxs GutSignal Decode™ helps connect symptom patterns, blood and urine tests, cross-sectional imaging, somatostatin receptor imaging, endoscopy, biopsy, Ki-67 findings, and stage into a more usable diagnosis.
Some NETs are discovered incidentally. Others cause flushing, diarrhea, wheezing, recurrent ulcers, low blood sugar, or other hormone-related symptoms, depending on the hormone produced.
CT, MRI, ultrasound, endoscopy, or endoscopic ultrasound may define the primary tumor and nearby structures. Somatostatin receptor PET can identify receptor-positive disease and help determine spread and treatment options.
Biopsy is central because pathology distinguishes a well-differentiated neuroendocrine tumor from a poorly differentiated neuroendocrine carcinoma and reports proliferation measures such as Ki-67 that help predict behavior.
GastroDoxs GutGuardians™
Your guardians. GastroDoxs GutGuardians™ is an elite team of board-certified gastroenterologists - a physician-led defense force of specialists, systems, and solution pathways working together to protect, detect, solve, and defend your digestive health through expert GI evaluation, advanced diagnostic screening, and endoscopic evaluation - commanded from your first concern to your last follow-up, and every critical stage in between.
GastroDoxs GutSignal Decode™
Your answers. GastroDoxs GutSignal Decode™ cracks your body's distress codes - delivering expert gastroenterologist interpretation of your GI symptoms, lab results, endoscopy findings, conditions, and digestive imaging across the full spectrum of digestive disease - translating every signal your gut sends into a confirmed diagnosis and a clear, board-certified plan of attack built entirely around you.
Neuroendocrine Tumor Diagnostic Matrix
| Finding or Question | Why It Matters | Likely Next Step |
|---|---|---|
| Incidental pancreatic or intestinal lesion | The lesion may be a NET, another tumor, or a benign finding. | Use organ-specific imaging and obtain tissue when it will change management. |
| Flushing and chronic diarrhea | A functional NET is one possibility, but medicines, menopause, mast-cell disorders and common GI conditions can mimic it. | Select biochemical testing and imaging based on the full pattern. |
| Biopsy confirms NET with elevated Ki-67 | Ki-67 helps assign grade and estimate growth behavior. | Complete staging and multidisciplinary treatment review. |
Neuroendocrine Tumor Diagnostic Follow-Up
GastroDoxs can review gastrointestinal symptoms, endoscopy findings, pancreatic or bowel imaging, biopsy reports, hormone-related concerns, and the need for advanced endoscopic testing.
Depending on the findings, the next step may include tissue sampling, pathology review, staging imaging, symptom control, surveillance, oncology referral, or multidisciplinary treatment planning.
Medical Review & Clinical Accuracy
This neuroendocrine tumor diagnosis guide is written for patient education and reviewed for digestive-health accuracy.
NET behavior varies widely by primary site, differentiation, grade, stage, and hormone activity. Individual prognosis and treatment cannot be determined from one marker or scan alone.
Our Expert Gastroenterologists
Neuroendocrine Tumors evaluation at GastroDoxs is guided by experienced digestive specialists who help connect symptoms, testing, and next-step care.
Patient Journey: From Unexplained Symptoms or a Scan Finding to NET Classification
Condition Uncertainty
The patient is concerned about neuroendocrine tumors but is not sure what the diagnosis means or which symptoms matter.
Pattern Becomes Clearer
Symptoms, risk factors, lab results, imaging, or prior findings begin to show a pattern that needs medical interpretation.
Diagnostic Evaluation
A GI evaluation helps review history, warning signs, possible causes, and whether testing or referral is needed.
Specialist Interpretation
The gastroenterologist connects symptoms, test results, and clinical findings to explain the most appropriate next step.
Clear Next Step
The patient leaves with a clearer plan for monitoring, treatment, testing, referral, or follow-up care.
Frequently Asked Questions About Neuroendocrine Tumor Diagnosis
Neuroendocrine tumors are abnormal growths that begin in cells with nerve-like and hormone-producing features. They can arise in the digestive tract, pancreas, lungs, and other organs.
Most occur sporadically from acquired cellular changes, and the exact cause is unknown. A minority are linked to inherited syndromes such as MEN1 or von Hippel-Lindau disease.
Symptoms depend on the organ and whether the tumor releases hormones. Possible signs include pain, diarrhea, flushing, wheezing, low blood sugar, ulcers, jaundice, bleeding, obstruction, or weight loss.
Diagnosis may use targeted blood or urine tests, CT or MRI, endoscopy or EUS, somatostatin receptor PET, and biopsy with pathology grading and staging.
NETs have malignant potential and can invade or spread, but behavior ranges from very slow-growing to highly aggressive. Pathology distinguishes well-differentiated NETs from neuroendocrine carcinomas.
Treatment may include surgery, surveillance, somatostatin analogs, targeted therapy, chemotherapy, liver-directed treatment, radiation, or peptide receptor radionuclide therapy.
Some localized NETs can be cured with complete removal. Advanced disease may not be curable but can sometimes be controlled for long periods with several treatment options.
Stage describes tumor size and invasion, lymph node involvement, and distant spread. The exact staging system depends on the organ where the tumor began.
Common primary sites include the small intestine, appendix, rectum, stomach, pancreas, and lungs, but neuroendocrine tumors can arise in several other organs.
Risk may be higher with certain inherited syndromes, family history, age, and some organ-specific factors. Most patients do not have a clear preventable risk factor.
Yes. NETs can spread to lymph nodes, liver, bone, lungs, or other tissues. The risk depends on primary site, size, grade, differentiation, and stage.
Survival varies too widely for one useful number. Primary site, grade, differentiation, stage, surgical removal, receptor status, and treatment response all affect outlook.
Some well-differentiated NETs grow slowly over years, while high-grade tumors and neuroendocrine carcinomas may progress quickly. Ki-67 and interval imaging help estimate growth behavior.
They are uncommon compared with major cancers, but detection has increased as imaging and pathology have improved.
Most cannot be prevented because the cause is unknown. People with an inherited syndrome may benefit from genetic counseling and planned surveillance.
Seek evaluation for persistent unexplained flushing, diarrhea, low blood sugar, ulcers, weight loss, jaundice, abdominal pain, bleeding, or a suspicious lesion found on imaging or endoscopy.
Clarify the Type, Grade and Next Step
A neuroendocrine tumor diagnosis becomes actionable only after the primary site, hormone activity, pathology, grade, stage, and imaging are reviewed together.